Atsena Gets FDA Nod to Expand XLRS Gene Therapy Clinical Trial to Include Pivotal Phase 3 Cohort
July 10, 2025
July 10, 2025
COLUMBIA, Maryland, July 10 -- The Foundation Fighting Blindness issued the following news:
* * *
Atsena Gets FDA Nod to Expand XLRS Gene Therapy Clinical Trial to Include Pivotal Phase 3 Cohort
The expanded Phase 1/2/3 shortens time to potential FDA approval.
*
Atsena Therapeutics, a developer of innovative gene therapies for inherited retinal diseases, has received agreement from the US Food & Drug Administration (FDA) to exp . . .
* * *
Atsena Gets FDA Nod to Expand XLRS Gene Therapy Clinical Trial to Include Pivotal Phase 3 Cohort
The expanded Phase 1/2/3 shortens time to potential FDA approval.
*
Atsena Therapeutics, a developer of innovative gene therapies for inherited retinal diseases, has received agreement from the US Food & Drug Administration (FDA) to exp . . .